Non‐fasting, morning blood samples were obtained by venipuncture and processed for plasma. Plasma p‐tau217 concentrations were measured using a novel single‐molecule array (Simoa) assay developed by Janssen Research and Development.
4 (link),
24 ,
25 (link) The functional plasma p‐tau217 assay range, accounting for sample dilution, was: lower limit of detection (LLOD) = 0.0011 pg/mL, lower limit of quantification (LLOQ) = 0.0187 g/mL, upper limit of quantification (ULOQ) = 10 pg/mL. All samples were > LLOD. GFAP and NfL concentrations were measured using the Neurology 2‐Plex B kit (Quanterix Simoa). Samples were measured in duplicate and all participants eligible for the present analysis had samples with coefficients of variance (CV) < 20%. Mean ± standard deviation CV% for study samples was 4.4% ± 3.4% (p‐tau217), 4.6% ± 3.7% (GFAP) and 4.8% ± 7.7% (NfL).
4 (link),
24 ,
25 (link) The functional plasma p‐tau217 assay range, accounting for sample dilution, was: lower limit of detection (LLOD) = 0.0011 pg/mL, lower limit of quantification (LLOQ) = 0.0187 g/mL, upper limit of quantification (ULOQ) = 10 pg/mL. All samples were > LLOD. GFAP and NfL concentrations were measured using the Neurology 2‐Plex B kit (Quanterix Simoa). Samples were measured in duplicate and all participants eligible for the present analysis had samples with coefficients of variance (CV) < 20%. Mean ± standard deviation CV% for study samples was 4.4% ± 3.4% (p‐tau217), 4.6% ± 3.7% (GFAP) and 4.8% ± 7.7% (NfL).
